Last reviewed · How we verify

ADH -1 and carboplatin

Adherex Technologies, Inc. · Phase 1 active Small molecule

ADH -1 and carboplatin is a Angiogenesis inhibitor and platinum-based chemotherapy Small molecule drug developed by Adherex Technologies, Inc.. It is currently in Phase 1 development for Non-small cell lung cancer.

Antiangiogenic and platinum-based chemotherapy

Antiangiogenic and platinum-based chemotherapy Used for Non-small cell lung cancer.

At a glance

Generic nameADH -1 and carboplatin
SponsorAdherex Technologies, Inc.
Drug classAngiogenesis inhibitor and platinum-based chemotherapy
TargetVEGF
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 1

Mechanism of action

ADH-1 is an angiogenesis inhibitor that works by targeting vascular endothelial growth factor (VEGF), while carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ADH -1 and carboplatin

What is ADH -1 and carboplatin?

ADH -1 and carboplatin is a Angiogenesis inhibitor and platinum-based chemotherapy drug developed by Adherex Technologies, Inc., indicated for Non-small cell lung cancer.

How does ADH -1 and carboplatin work?

Antiangiogenic and platinum-based chemotherapy

What is ADH -1 and carboplatin used for?

ADH -1 and carboplatin is indicated for Non-small cell lung cancer.

Who makes ADH -1 and carboplatin?

ADH -1 and carboplatin is developed by Adherex Technologies, Inc. (see full Adherex Technologies, Inc. pipeline at /company/adherex-technologies-inc).

What drug class is ADH -1 and carboplatin in?

ADH -1 and carboplatin belongs to the Angiogenesis inhibitor and platinum-based chemotherapy class. See all Angiogenesis inhibitor and platinum-based chemotherapy drugs at /class/angiogenesis-inhibitor-and-platinum-based-chemotherapy.

What development phase is ADH -1 and carboplatin in?

ADH -1 and carboplatin is in Phase 1.

What are the side effects of ADH -1 and carboplatin?

Common side effects of ADH -1 and carboplatin include Neutropenia, Thrombocytopenia, Anemia.

What does ADH -1 and carboplatin target?

ADH -1 and carboplatin targets VEGF and is a Angiogenesis inhibitor and platinum-based chemotherapy.

Related